Drug Approval | May 25, 2026
Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Subscribe To Our Newsletter & Stay Updated
